SCHEMBL5281760

SCHEMBL5281760

COCCCOc1cc(C(=O)O)ccc1C#C[Si](C)(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.46
HPGD P15428 1/20 0.46
TSHR P16473 1/20 0.41
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA4 P22748 1/20 0.40
CA6 P23280 1/20 0.40
CA7 P43166 1/20 0.40
TPMT P51580 1/20 0.40
CA9 Q16790 1/20 0.40
CA14 Q9ULX7 1/20 0.40
PTGER4 P35408 1/20 0.40
POLB P06746 1/20 0.39
CASP6 P55212 1/20 0.39
TTR P02766 2/20 0.38
ALB P02768 1/20 0.38
HTT P42858 1/20 0.38
PLA2G4B P0C869 1/20 0.38
HCAR3 P49019 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2930875 0.89 TTR (0.41) ALDH1A1HPGDCA12CA1CA2
SCHEMBL7930623 0.87 XDH (0.49) ALDH1A1HPGDTSHRCA12CA1
SCHEMBL2932997 0.82 ALDH1A1 (0.50) ALDH1A1HPGDTSHRCA12CA1
SCHEMBL6580918 0.80 MAP4K4 (0.52) HPGD
SCHEMBL15955711 0.80 ALDH1A1 (0.49) ALDH1A1HPGD
SCHEMBL8175421 0.76 EGFR (0.44) ALDH1A1HPGDCA12CA1CA2
SCHEMBL2936694 0.76 TSHR (0.53) ALDH1A1HPGDTSHRCA12CA1
SCHEMBL30683868 0.76 TSHR (0.69) TSHRCA12CA1CA2CA4
SCHEMBL22160237 0.76 PTPN11 (0.50) TSHRCA12CA1CA2CA4
SCHEMBL89386 0.76 TSHR (0.69) TSHRCA12CA1CA2CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1836163-A2 PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN Novartis AG (CH) 2007-09-26 EP disclosed
WO-2006066896-A2 PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN NOVARTIS AG (CH) 2006-06-29 WO disclosed